Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow JNJ by emailGet an email when JNJ pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about JNJ, unsubscribe in one click. Privacy
📣 What JNJ Says Is Next
fourth-quarter · “Company issues guidance for 2026 with estimated reported sales of $100.5 Billion or 6.7% at the midpoint, and adjusted EPS 4 of $11.53 or 6.9% at the midpoint New Brunswick, N.J. (January 21, 2026) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025.”
Company press release, Jan 21, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full JNJ picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JNJ and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.